DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: LEMTRADA (Campath, alemtuzumab)
*****************************************************
#Post#: 1349--------------------------------------------------
(Abst.) Alemtuzumab beats Rebif for RRMS in MRI endpoints
By: agate Date: September 4, 2016, 7:35 pm
---------------------------------------------------------
From PubMed, September 4, 2016:
[quote]Neurology. 2016 Sep 2.
Superior MRI outcomes with alemtuzumab compared with
subcutaneous interferon β-1a in MS
Arnold DL, Fisher E, Brinar VV, Cohen JA, Coles AJ, Giovannoni
G, Hartung HP, Havrdova E, Selmaj KW, Stojanovic M, Weiner HL,
Lake SL, Margolin DH, Thomas DR, Panzara MA, Compston DA;
CARE-MS I and CARE-MS II Investigators.
Collaborators (230)
OBJECTIVE:
To describe detailed MRI results from 2 head-to-head phase III
trials, Comparison of Alemtuzumab and Rebif Efficacy in Multiple
Sclerosis Study I (CARE-MS I; NCT00530348) and Study II (CARE-MS
II; NCT00548405), of alemtuzumab vs subcutaneous interferon
β-1a (SC IFN-β-1a) in patients with active
relapsing-remitting multiple sclerosis (RRMS).
METHODS:
The impact of alemtuzumab 12 mg vs SC IFN-β-1a 44 μg
on MRI measures was evaluated in patients with RRMS who were
treatment-naive (CARE-MS I) or who had an inadequate response,
defined as at least one relapse, to prior therapy (CARE-MS II).
RESULTS:
Both treatments prevented T2-hyperintense lesion volume
increases from baseline. Alemtuzumab was more effective than SC
IFN-β-1a on most lesion-based endpoints in both studies (p
< 0.05), including decreased risk of new/enlarging T2 lesions
over 2 years and gadolinium-enhancing lesions at year 2. Reduced
risk of new T1 lesions (p < 0.0001) and gadolinium-enhancing
lesion conversion to T1-hypointense black holes (p = 0.0078)
were observed with alemtuzumab vs SC IFN-β-1a in CARE-MS
II. Alemtuzumab slowed brain volume loss over 2 years in CARE-MS
I (p < 0.0001) and II (p = 0.012) vs SC IFN-β-1a.
CONCLUSIONS:
Alemtuzumab demonstrated greater efficacy than SC IFN-β-1a
on MRI endpoints in active RRMS. The superiority of alemtuzumab
was more prominent during the second year of both studies. These
findings complement the superior clinical efficacy of
alemtuzumab over SC IFN-β-1a in RRMS.
CLINICALTRIALSGOV IDENTIFIER:
NCT00530348 and NCT00548405.
CLASSIFICATION OF EVIDENCE:
The results reported here provide Class I evidence that, for
patients with active RRMS, alemtuzumab is superior to SC
IFN-β-1a on multiple MRI endpoints.[/quote]
The abstract can be seen here
HTML http://www.ncbi.nlm.nih.gov/pubmed/27590291.
*****************************************************